All posts by: Michael Zand

About Michael Zand

Eiger Sells Cardiovascular Gene Therapy to Theragene in $18.1M Deal – Pharmaceutical Processing

Continue reading

2017-06-29 NEWS

Pharmaceutical Processing

Eiger Sells Cardiovascular Gene Therapy to Theragene in $18.1M Deal
Pharmaceutical Processing
Eiger BioPharmaceuticals announced an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a). Financial terms of the agreement include a total upfront of $3.1 million in …
Eiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stockSeeking Alpha

all 6 news articles »

Continue reading

2017-06-29 NEWS

Can CRISPR Conquer Huntington’s?
PLoS Blogs (blog)
I set a high bar for writing about mouse studies. I don’t include them in my textbooks or news articles, and only rarely blog about them. But when experiments in mice shine a glimmer of hope on a horrific illness with a long history of failed

Continue reading

2017-06-29 NEWS

PLoS Blogs (blog)

Can CRISPR Conquer Huntington’s? | DNA Science Blog
PLoS Blogs (blog)
I set a high bar for writing about mouse studies. I don’t include them in my textbooks or news articles, and only rarely blog about them. But when experiments in …
Gene Editing Reverses Huntington’s in Mouse StudyBioscience Technology

all 2 news articles »

Continue reading

2017-06-29 NEWS

The Pharma Letter (registration)

Servier embarks on another collaboration in immuno-oncology
The Pharma Letter (registration)
France’s Servier Laboratories and Transgene have started working together to try to develop simpler, faster and more effective ways of engineering CAR-T cell …
Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic …PharmiWeb.com (press release)

all 6 news articles »

Continue reading

2017-06-29 NEWS

Weekly Register

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy
Nasdaq
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced …
Is Abeona Therapeutics Incorporated (NASDAQ:ABEO)’s Fuel Running Low? Reports Show More SellersWeekly Register

all 17 news articles »